{"brief_title": "Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus", "brief_summary": "Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.", "condition": ["Staphylococcal Skin Infection"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Telavancin", "Vancomycin"], "description": ["Telavancin 10 mg/kg/day, IV for up to 14 days.", "Vancomycin 1 Gm IV q 12 hrs for up to 14 days."], "arm_group_label": ["Telavancin", "Vancomycin"], "other_name": ["VIBATIV", "TD-6424"], "criteria": "Inclusion Criteria: - Patients must have a diagnosis of one of the following complicated skin and skin structure infections with Methicillin Resistant Staphylococcus aureus (MRSA) either suspected or confirmed as the major cause of the infection: - major abscess requiring surgical incision and drainage - infected burn (see exclusion criteria for important qualifications) - deep/extensive cellulitis - infected ulcer (see exclusion criteria for important qualifications) - wound infections - Patients must be expected to require at least 7 days of intravenous antibiotic treatment Exclusion Criteria: - Received more than 24 hours of potentially effective systemic (IV, IM or PO) antibiotic therapy prior to randomization - Burns involving > 20% of body surface area or third-degree/full-thickness in nature, diabetic foot ulcers, ischemic ulcers/wounds, necrotizing fascitis, gas gangrene, or mediastinitis.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "cSSSI", "mesh_term": ["Infection", "Communicable Diseases", "Staphylococcal Infections", "Skin Diseases, Infectious", "Staphylococcal Skin Infections", "Vancomycin", "Methicillin", "Telavancin"], "id": "NCT00091819"}